Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

430
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
430
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

154
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
154
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

127
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
127
Inhaled Medications01:23

Inhaled Medications

679
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
679
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

414
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
414
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alpha-2 antiplasmin deficiency: a rare fibrinolytic disorder identified after decades of diagnostic delay.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same author

[Late complications after atrial fibrillation ablation : Diagnosis and management].

Herzschrittmachertherapie & Elektrophysiologie·2026
Same author

An Abbreviated Assessment Tool for Detection of Pulmonary Hypertension in Patients With Interstitial Lung Disease.

Pulmonary circulation·2026
Same author

Discovery of gene-alcohol interaction loci influencing blood pressure in 1.1 million individuals from multiple populations.

Research square·2026
Same author

Diffuse Alveolar Hemorrhage in Lymphangioleiomyomatosis.

Chest·2026
Same author

Comparative analysis of <math><mrow><msub><mrow><mover><mi>V</mi> <mo>Ë™</mo></mover> <mi>O</mi></mrow> <mn>2</mn></msub></mrow></math> prediction equations using a novel web-based application: an illustrative example in formerly deployed military veterans.

Frontiers in physiology·2026
Same journal

Usability and Acceptance of Autoinjector and Prefilled Syringe Devices by Patients with Generalized Myasthenia Gravis in a Human Factors Study.

Advances in therapy·2026
Same journal

Treatment Patterns and Decision Drivers in Chinese Patients with Locally Advanced Cervical Cancer: Results from a National Physician Survey.

Advances in therapy·2026
Same journal

Matching-Adjusted Indirect Comparison of Tarlatamab for Patients with Platinum-Refractory or Platinum-Resistant Extensive-Stage Small-Cell Lung Cancer.

Advances in therapy·2026
Same journal

Sacral Neuromodulation for Refractory Overactive Bladder: Closing the Gaps in Anatomy, Mechanisms, and Parameter Selection.

Advances in therapy·2026
Same journal

Exploring the Impact of Delivering Allergy Medication as Self-Care on Healthcare Greenhouse Gas Emissions in the United Kingdom.

Advances in therapy·2026
Same journal

Management of Persistent Storage Symptoms and Overactive Bladder in Men Diagnosed with Benign Prostatic Hyperplasia: A Narrative Review.

Advances in therapy·2026
See all related articles

Related Experiment Video

Updated: Jan 6, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.4K

Transitioning Between Treprostinil Formulations: Evidence and Strategies.

Megan Clarke1, Ali Ataya2, Alison M Turkin3

  • 1Novant Health New Hanover Regional Medical Center, Wilmington, NC, USA.

Advances in Therapy
|November 10, 2025
PubMed
Summary
This summary is machine-generated.

Transitioning between treprostinil formulations for pulmonary arterial hypertension is common but lacks guidance. This review of over 100 patients shows an 80% success rate with individualized strategies, highlighting the need for tailored approaches.

Keywords:
PharmacokineticsProstacyclin pathway-targeted therapyPulmonary hypertensionRoute of administrationTransitionsTreprostinil

More Related Videos

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
08:38

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia

Published on: August 28, 2013

26.0K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.4K

Related Experiment Videos

Last Updated: Jan 6, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.4K
Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
08:38

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia

Published on: August 28, 2013

26.0K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.4K

Area of Science:

  • Pharmacology
  • Pulmonary Medicine
  • Clinical Pharmacy

Background:

  • Treprostinil, a prostacyclin analog, treats pulmonary arterial hypertension (PAH) and pulmonary hypertension with interstitial lung disease (PH-ILD).
  • Multiple treprostinil formulations exist (parenteral, oral, inhaled), necessitating frequent patient transitions.
  • Standardized guidance for transitioning between treprostinil formulations is currently lacking in clinical practice.

Purpose of the Study:

  • To review and summarize existing evidence on the safety, efficacy, and techniques for transitioning between different treprostinil formulations.
  • To provide a consolidated resource for clinicians managing treprostinil therapy transitions.
  • To inform the development of individualized transition strategies for patients with PAH and PH-ILD.

Main Methods:

  • Systematic review of published literature on treprostinil formulation transitions.
  • Inclusion of data from over 100 patients across various clinical settings.
  • Analysis of reported transition strategies, focusing on crossover methods.

Main Results:

  • Crossover transition strategies were most commonly employed.
  • Approximately 80% of reviewed cases were considered successful, though definitions of success varied.
  • Unsuccessful transitions were frequently associated with disease progression or treatment intolerance.

Conclusions:

  • Individualized transition strategies are crucial, considering patient clinical status, preferences, and formulation pharmacokinetics.
  • Optimizing transitions is key to maintaining therapeutic continuity and improving outcomes for patients on treprostinil.
  • Further research with standardized success metrics is needed to refine transition protocols.